Diabetes Patients on GLP-1 Therapies May Face Higher Risk of Macular Degeneration
A recent study published in JAMA Ophthalmology has found that diabetes patients who use GLP-1 therapies are twice as likely to develop neovascular age-related macular degeneration (nAMD) compared to those who don’t take the medications. The condition, which causes vision loss due to decreased blood supply to the optic nerve, affects millions of people worldwide. … Read more